(4aS,8aR)-3,4,4a,5,6,7,8,8a-octahydro-2H-benzo[b][1,4]oxazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: (4aS,8aR)-3,4,4a,5,6,7,8,8a-octahydro-2H-benzo[b][1,4]oxazine
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: AGYZKRGPZJEWPN-JGVFFNPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE MTOR
  申请人：ANGEX PHARMACEUTICAL INC

  公开号：WO2021133509A1

  公开（公告）日：2021-07-01

  The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

  本公开描述了新颖的杂环mTOR抑制剂以及其制备方法。还描述了包含这些mTOR抑制剂的药物组合物以及治疗癌症、传染病和其他mTOR相关疾病的使用方法。
• Amido-Thiophene Compounds and Their Use
  申请人：Webster Scott Peter

  公开号：US20130012545A1

  公开（公告）日：2013-01-10

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明通常涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其在其他方面抑制11β-羟化固醇脱氢酶1型（11β-HSD1）。本发明还涉及包括这些化合物的制药组合物，并且在体内外使用这些化合物和组合物来抑制11β-羟化固醇脱氢酶1型；治疗通过抑制11β-羟化固醇脱氢酶1型改善的疾病；治疗代谢综合征，包括2型糖尿病和肥胖症等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢紊乱和缺血性（冠状动脉）心脏病等心血管疾病；治疗CNS疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。
• AMIDO-THIOPHENE COMPOUNDS AND THEIR USE
  申请人：THE UNIVERSITY OF EDINBURGH

  公开号：EP2283004B1

  公开（公告）日：2015-05-27
• US8299063B2
  申请人：——

  公开号：US8299063B2

  公开（公告）日：2012-10-30
• US8614209B2
  申请人：——

  公开号：US8614209B2

  公开（公告）日：2013-12-24